Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtideFRA:FQ2 -6.03%31 EV-to-EBIT is 8.08 as of Sep. 02, 2026, which is 9% below its 10-year median of 8.86. GuruFocus rates FRA:FQ2 with a GF Score™ of 31/100. Among 367 Biotechnology companies, Medtide ranks better than 60.76% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medtide's Enterprise Value is €198.49 Mil.
Medtide's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €24.57 Mil. Therefore, Medtide's EV-to-EBIT for today is 8.08.
The historical rank and industry rank for Medtide's EV-to-EBIT or its related term are showing as below:
FRA:FQ2'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.32 Med: 8.86 Max: 61.67
Current: 8.12
During the past 5 years, the highest EV-to-EBIT of Medtide was 61.67. The lowest was 5.32. And the median was 8.86.
FRA:FQ2's EV-to-EBIT is ranked better than 60.76% of 367
companies
in the Biotechnology industry
Industry Median: 15.78
vs FRA:FQ2: 8.12
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medtide's Enterprise Value for the quarter that ended in Dec. 2025 was €315.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medtide's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €24.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtide EV-to-EBIT Related Terms
Medtide EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medtide's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FQ2 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Medtide's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtide EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medtide's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medtide's EV-to-EBIT falls into.
Medtide's current Enterprise Value is €198.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medtide's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €24.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtide (FRA:FQ2) has a EV-to-EBIT of 8.08 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medtide and its competitors. This is near median its historical median of 8.86. Over the past decade, Medtide's EV-to-EBIT has ranged from 5.32 to 61.67. According to the industry distribution chart, Medtide ranks #144 out of 367 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Medtide's EV-to-EBIT too high?
Medtide's current EV-to-EBIT of 8.08 is near median its 10-year median of 8.86. Over the past 10 years, this metric has ranged from a low of 5.32 to a high of 61.67. The Biotechnology industry median EV-to-EBIT is 15.78. Medtide's value of 8.08 is 48.8% below this industry median. Based on the distribution chart, Medtide ranks #144 out of 367 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medtide has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medtide ranks #144 out of 367 companies for EV-to-EBIT. This puts Medtide in the upper half of its industry. The industry median EV-to-EBIT is 15.78. Medtide's value of 8.08 is 48.8% below this benchmark. Historically, Medtide's own EV-to-EBIT has ranged from 5.32 to 61.67 over the past decade. While the company's 10-year median is 8.86 vs. the industry median of 15.78, Medtide has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.78, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtide's current EV-to-EBIT of 8.08 is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medtide and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtide's current EV-to-EBIT is 8.08, which is near median its own 10-year median of 8.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (FRA:FQ2) has a current EV-to-EBIT of 8.08. The current EV-to-EBIT is 8.08, which is near median its 10-year median of 8.86 and 48.8% below the Biotechnology industry median of 15.78. Medtide's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medtide (FRA:FQ2), the current EV-to-EBIT is 8.08 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
31GF Score
Get the complete analysis for FRA:FQ2
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FQ2 has been successfully added to your 
